{"version":"company-facts.v1","source":"https://secwatch.observer","generated_at":"2026-09-01T13:42:26.454569+00:00","company":{"ticker":"TARA","cik":1359931,"company_name":"Protara Therapeutics, Inc."},"pagination":{"limit":100,"returned":32,"next_cursor":null},"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer","counterparties":{"contract_counterparty":[{"display_name":"J.P. Morgan Securities LLC, TD Securities LLC and Piper Sandler & Co.","detail":"underwriting","count":1,"first_seen":"2025-12-08T23:59:59+00:00","last_seen":"2025-12-08T23:59:59+00:00","evidence_fact_ids":[132515]}]},"facts":[{"fact_type":"shareholder_vote","fact_key":"7b0069b11013e019235023eb2b940b19d62adf1b","cik":1359931,"ticker":"TARA","company_name":"Protara Therapeutics, Inc.","filed_at":"2026-06-15T20:05:37+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2026-06-12","outcome":"passed","proposal_text":"Approval of an Amendment to the Company’s Sixth Amended and Restated Certificate of Incorporation Allowing Officer Exculpation as Permitted by Delaware Law","proposal_type":"charter_amendment","results":[{"broker_non_votes":"14,185,811","subject":null,"votes_abstain":"36,217","votes_against":"1,235,007","votes_for":"29,642,641","votes_withheld":null}]},"claim":"Protara Therapeutics, Inc. shareholders approved Approval of an Amendment to the Company’s Sixth Amended and Restated Certificate of Incorporation Allowing Officer Exculpation as Permitted by Delaware Law at the 2026-06-12 meeting.","evidence_excerpt":"Proposal 7. Approval of an Amendment to the Company’s Sixth Amended and Restated Certificate of Incorporation Allowing Officer Exculpation as Permitted by Delaware Law. The Company’s stockholders approved the amendment to the Company’s sixth amended and restated certificate of incorporation allowing officer exculpation as permitted by Delaware law. The final voting results are as follows: Votes For Votes Against Abstentions Broker Non-Votes 29,642,641 1,235,007 36,217 14,185,811","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001213900-26-068774","anchor_url":"https://secwatch.observer/filing/0001213900-26-068774#claim-7b0069b11013e019235023eb2b940b19d62adf1b","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1359931/000121390026068774/0001213900-26-068774-index.htm"},{"fact_type":"shareholder_vote","fact_key":"8a19169f6c9931c1b60386eff771b811a8125436","cik":1359931,"ticker":"TARA","company_name":"Protara Therapeutics, Inc.","filed_at":"2026-06-15T20:05:37+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2026-06-12","outcome":"passed","proposal_text":"Approval of an Amendment to the Company’s Sixth Amended and Restated Certificate of Incorporation to Increase the Number of Authorized Shares of Common Stock from 100,000,000 to 200,000,000","proposal_type":"charter_amendment","results":[{"broker_non_votes":null,"subject":null,"votes_abstain":"26,639","votes_against":"2,655,416","votes_for":"42,417,621","votes_withheld":null}]},"claim":"Protara Therapeutics, Inc. shareholders approved Approval of an Amendment to the Company’s Sixth Amended and Restated Certificate of Incorporation to Increase the Number of Authorized Shares of Common Stock from 100,000,000 to 200,000,000 at the 2026-06-12 meeting.","evidence_excerpt":"Proposal 6. Approval of an Amendment to the Company’s Sixth Amended and Restated Certificate of Incorporation to Increase the Number of Authorized Shares of Common Stock from 100,000,000 to 200,000,000. The Company’s stockholders approved the amendment to the Company’s sixth amended and restated certificate of incorporation to increase the authorized number of the Company’s common stock, par value $0.001 per share, from 100,000,000 to 200,000,000. The final voting results are as follows: Votes For Votes Against Abstentions 42,417,621 2,655,416 26,639","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001213900-26-068774","anchor_url":"https://secwatch.observer/filing/0001213900-26-068774#claim-8a19169f6c9931c1b60386eff771b811a8125436","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1359931/000121390026068774/0001213900-26-068774-index.htm"},{"fact_type":"shareholder_vote","fact_key":"0976cee1bf757b699acc1e64592a13fe604ce945","cik":1359931,"ticker":"TARA","company_name":"Protara Therapeutics, Inc.","filed_at":"2026-06-15T20:05:37+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2026-06-12","outcome":"passed","proposal_text":"Approval of an Amendment to the Protara Therapeutics, Inc. 2024 Equity Incentive Plan","proposal_type":"equity_plan","results":[{"broker_non_votes":"14,185,811","subject":null,"votes_abstain":"25,879","votes_against":"12,793,033","votes_for":"18,094,953","votes_withheld":null}]},"claim":"Protara Therapeutics, Inc. shareholders approved Approval of an Amendment to the Protara Therapeutics, Inc. 2024 Equity Incentive Plan at the 2026-06-12 meeting.","evidence_excerpt":"Proposal 5. Approval of an Amendment to the Protara Therapeutics, Inc. 2024 Equity Incentive Plan. The Company’s stockholders approved the amendment to the Protara Therapeutics, Inc. 2024 Equity Incentive Plan, as disclosed in the Company’s definitive proxy statement for the Annual Meeting. The final voting results are as follows: Votes For Votes Against Abstentions Broker Non-Votes 18,094,953 12,793,033 25,879 14,185,811","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001213900-26-068774","anchor_url":"https://secwatch.observer/filing/0001213900-26-068774#claim-0976cee1bf757b699acc1e64592a13fe604ce945","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1359931/000121390026068774/0001213900-26-068774-index.htm"},{"fact_type":"shareholder_vote","fact_key":"b5dbb3d74663e3265b3045ecc619d5bcce13d44a","cik":1359931,"ticker":"TARA","company_name":"Protara Therapeutics, Inc.","filed_at":"2026-06-15T20:05:37+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2026-06-12","outcome":"passed","proposal_text":"Vote, on an Advisory Basis, on the Frequency of the Say-On-Pay vote","proposal_type":"say_on_pay_frequency","results":[{"broker_non_votes":"14,185,811","subject":null,"votes_abstain":"44,372","votes_against":"4,102,669","votes_for":"26,766,824","votes_withheld":null}]},"claim":"Protara Therapeutics, Inc. shareholders approved Vote, on an Advisory Basis, on the Frequency of the Say-On-Pay vote at the 2026-06-12 meeting.","evidence_excerpt":"Proposal 4. Vote, on an Advisory Basis, on the Frequency of the Say-On-Pay vote. The Company’s stockholders voted, on an advisory basis, that the stockholder advisory vote to approve the compensation of the Company’s named executive officers should occur every one year. The final voting results are as follows: One Year Two Years Three Years Abstentions Broker Non-Votes 26,766,824 660,775 3,441,894 44,372 14,185,811","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001213900-26-068774","anchor_url":"https://secwatch.observer/filing/0001213900-26-068774#claim-b5dbb3d74663e3265b3045ecc619d5bcce13d44a","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1359931/000121390026068774/0001213900-26-068774-index.htm"},{"fact_type":"shareholder_vote","fact_key":"ab1a43c9229e947fe50439e640889f193c067628","cik":1359931,"ticker":"TARA","company_name":"Protara Therapeutics, Inc.","filed_at":"2026-06-15T20:05:37+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2026-06-12","outcome":"passed","proposal_text":"Approval, on an Advisory Basis, of the Compensation of the Company’s Named Executive Officers","proposal_type":"say_on_pay","results":[{"broker_non_votes":"14,185,811","subject":null,"votes_abstain":"48,666","votes_against":"1,656,994","votes_for":"29,208,205","votes_withheld":null}]},"claim":"Protara Therapeutics, Inc. shareholders approved Approval, on an Advisory Basis, of the Compensation of the Company’s Named Executive Officers at the 2026-06-12 meeting.","evidence_excerpt":"Proposal 3. Approval, on an Advisory Basis, of the Compensation of the Company’s Named Executive Officers. The Company’s stockholders approved, on an advisory basis, the compensation of the Company’s named executive officers, as disclosed in the Company’s definitive proxy statement for the Annual Meeting. The final voting results are as follows: Votes For Votes Against Abstentions Broker Non-Votes 29,208,205 1,656,994 48,666 14,185,811","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001213900-26-068774","anchor_url":"https://secwatch.observer/filing/0001213900-26-068774#claim-ab1a43c9229e947fe50439e640889f193c067628","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1359931/000121390026068774/0001213900-26-068774-index.htm"},{"fact_type":"shareholder_vote","fact_key":"d761c8695bd1bb2096307aa76be396cc0416ab52","cik":1359931,"ticker":"TARA","company_name":"Protara Therapeutics, Inc.","filed_at":"2026-06-15T20:05:37+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2026-06-12","outcome":"passed","proposal_text":"Ratification of the Selection of Independent Registered Public Accounting Firm","proposal_type":"auditor_ratification","results":[{"broker_non_votes":null,"subject":null,"votes_abstain":"13,025","votes_against":"74,615","votes_for":"45,012,036","votes_withheld":null}]},"claim":"Protara Therapeutics, Inc. shareholders approved Ratification of the Selection of Independent Registered Public Accounting Firm at the 2026-06-12 meeting.","evidence_excerpt":"Proposal 2. Ratification of the Selection of Independent Registered Public Accounting Firm. The Company’s stockholders ratified the selection by the Company’s Audit Committee of the Board of Ernst and Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. The final voting results are as follows: Votes For Votes Against Abstentions 45,012,036 74,615 13,025","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001213900-26-068774","anchor_url":"https://secwatch.observer/filing/0001213900-26-068774#claim-d761c8695bd1bb2096307aa76be396cc0416ab52","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1359931/000121390026068774/0001213900-26-068774-index.htm"},{"fact_type":"shareholder_vote","fact_key":"905b36f95568e1c1a5aa1ae07111850f4064f4fa","cik":1359931,"ticker":"TARA","company_name":"Protara Therapeutics, Inc.","filed_at":"2026-06-15T20:05:37+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2026-06-12","outcome":"passed","proposal_text":"Election of Directors","proposal_type":"director_election","results":[{"broker_non_votes":"14,185,811","subject":"Jesse Shefferman","votes_abstain":null,"votes_against":null,"votes_for":"26,672,259","votes_withheld":"4,241,606"},{"broker_non_votes":"14,185,811","subject":"Barry Flannelly, Pharm.D.","votes_abstain":null,"votes_against":null,"votes_for":"25,409,066","votes_withheld":"5,504,799"},{"broker_non_votes":"14,185,811","subject":"Cynthia Smith","votes_abstain":null,"votes_against":null,"votes_for":"22,371,125","votes_withheld":"8,542,740"}]},"claim":"Protara Therapeutics, Inc. shareholders approved Election of Directors at the 2026-06-12 meeting.","evidence_excerpt":"Proposal 1. Election of Directors. The Company’s stockholders elected the three persons listed below as Class III directors, each to serve on the Company’s Board of Directors until the Company’s 2029 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified. The final voting results are as follows: Votes For Votes Withheld Broker Non-Votes Jesse Shefferman 26,672,259 4,241,606 14,185,811 Barry Flannelly, Pharm.D. 25,409,066 5,504,799 14,185,811 Cynthia Smith 22,371,125 8,542,740 14,185,811","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001213900-26-068774","anchor_url":"https://secwatch.observer/filing/0001213900-26-068774#claim-905b36f95568e1c1a5aa1ae07111850f4064f4fa","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1359931/000121390026068774/0001213900-26-068774-index.htm"},{"fact_type":"earnings_release","fact_key":"320647bea8b0c0f14c6a9c6c3630733f3e42f726","cik":1359931,"ticker":"TARA","company_name":"Protara Therapeutics, Inc.","filed_at":"2026-05-13T12:05:18+00:00","payload":{"eps_text":"$0.31 per share","guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"$17.8 million, or $0.31 per share","period_text":"the first quarter ended March 31, 2026","report_date":"2026-05-13","result_type":"reported_results","revenue_text":null},"claim":"Protara Therapeutics, Inc. reported the first quarter ended March 31, 2026 results: net income $17.8 million, or $0.31 per share, EPS $0.31 per share.","evidence_excerpt":"For the first quarter of 2026, Protara incurred a net loss of $17.8 million, or $0.31 per share, compared with a net loss of $11.9 million, or $0.29 per share, for the same period in 2025.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001213900-26-055462","anchor_url":"https://secwatch.observer/filing/0001213900-26-055462#claim-320647bea8b0c0f14c6a9c6c3630733f3e42f726","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1359931/000121390026055462/0001213900-26-055462-index.htm"},{"fact_type":"earnings_release","fact_key":"7b023951e82e71ce1ca735aa77ad1842a0d954a4","cik":1359931,"ticker":"TARA","company_name":"Protara Therapeutics, Inc.","filed_at":"2026-03-10T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"the full year ended December 31, 2025","report_date":"2026-03-10","result_type":"reported_results","revenue_text":null},"claim":"Protara Therapeutics, Inc. reported financial results for the full year ended December 31, 2025.","evidence_excerpt":"and for the full year increased to $42.6 million compared to $31.7 million for 2024","confidence":0.8,"filing_url":"https://secwatch.observer/filing/0001213900-26-025432","anchor_url":"https://secwatch.observer/filing/0001213900-26-025432#claim-7b023951e82e71ce1ca735aa77ad1842a0d954a4","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1359931/000121390026025432/0001213900-26-025432-index.htm"},{"fact_type":"earnings_release","fact_key":"594fbd6184af3425929e92ff2d468d4c124ffec1","cik":1359931,"ticker":"TARA","company_name":"Protara Therapeutics, Inc.","filed_at":"2026-03-10T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"the fourth quarter of 2025","report_date":"2026-03-10","result_type":"reported_results","revenue_text":null},"claim":"Protara Therapeutics, Inc. reported financial results for the fourth quarter of 2025.","evidence_excerpt":"Research and development expenses for the fourth quarter of 2025 increased to $13.1 million from $9.5 million for the prior year period","confidence":0.8,"filing_url":"https://secwatch.observer/filing/0001213900-26-025432","anchor_url":"https://secwatch.observer/filing/0001213900-26-025432#claim-594fbd6184af3425929e92ff2d468d4c124ffec1","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1359931/000121390026025432/0001213900-26-025432-index.htm"},{"fact_type":"material_agreement","fact_key":"709fa87cac7286873218b0541f8feb8c1df52e71","cik":1359931,"ticker":"TARA","company_name":"Protara Therapeutics, Inc.","filed_at":"2025-12-08T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Underwriting Agreement","agreement_type":"underwriting","counterparty":"J.P. Morgan Securities LLC, TD Securities (USA) LLC and Piper Sandler & Co., as representatives of the several underwriters","effective_date":"2025-12-04","item_codes_triggered":["1.01"],"value_text":"approximately $75 million"},"claim":"Protara Therapeutics, Inc. entered into Underwriting Agreement with J.P. Morgan Securities LLC, TD Securities (USA) LLC and Piper Sandler & Co., as representatives of the several underwriters valued at approximately $75 million (effective 2025-12-04).","evidence_excerpt":"On December 4, 2025, Protara Therapeutics, Inc. (the “Company”) entered into an Underwriting Agreement (the “Underwriting Agreement”) with J.P. Morgan Securities LLC, TD Securities (USA) LLC and Piper Sandler & Co., as representatives (the “Representatives”) of the several underwriters named therein (collectively, the “Underwriters”), pursuant to which the Company agreed to sell and issue to the Underwriters an aggregate of 13,043,479 shares (the “Shares”) of common stock of the Company, par value $0.001 per share (the “Common Stock”) (the “Offering”).","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001213900-25-119242","anchor_url":"https://secwatch.observer/filing/0001213900-25-119242#claim-709fa87cac7286873218b0541f8feb8c1df52e71","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1359931/000121390025119242/0001213900-25-119242-index.htm"},{"fact_type":"earnings_release","fact_key":"10e20cbe24a3fb7a259477e3e2249a5d1646a947","cik":1359931,"ticker":"TARA","company_name":"Protara Therapeutics, Inc.","filed_at":"2024-05-02T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"first quarter ended March 31, 2024","report_date":"2024-05-02","result_type":"reported_results","revenue_text":null},"claim":"Protara Therapeutics, Inc. reported financial results for first quarter ended March 31, 2024.","evidence_excerpt":"On May 2, 2024, Protara Therapeutics, Inc. (the \"Company\") announced its financial results for the quarter ended March 31, 2024 in the press release attached hereto as Exhibit 99.1 and incorporated herein by reference.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001213900-24-038756","anchor_url":"https://secwatch.observer/filing/0001213900-24-038756#claim-10e20cbe24a3fb7a259477e3e2249a5d1646a947","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1359931/000121390024038756/0001213900-24-038756-index.htm"},{"fact_type":"material_agreement","fact_key":"3360232f69db4ca2e231eb3dd0fdc6cd89106f40","cik":1359931,"ticker":"TARA","company_name":"Protara Therapeutics, Inc.","filed_at":"2024-04-05T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Registration Rights Agreement","agreement_type":"equity_purchase","counterparty":"the Purchasers","effective_date":"2024-04-05","item_codes_triggered":["1.01"],"value_text":null},"claim":"Protara Therapeutics, Inc. entered into Registration Rights Agreement with the Purchasers (effective 2024-04-05).","evidence_excerpt":"In connection with the Private Placement, the Company also entered into a registration rights agreement, dated April 5, 2024 (the “Registration Rights Agreement”), with the Purchasers that requires, among other things, the Company to file a resale registration statement with the Securities and Exchange Commission (the “SEC”) within 30 days after the Closing to register the resale of the Shares and the shares of Common Stock underlying each of the Pre-Funded Warrants and the Common Warrants.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001213900-24-030623","anchor_url":"https://secwatch.observer/filing/0001213900-24-030623#claim-3360232f69db4ca2e231eb3dd0fdc6cd89106f40","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1359931/000121390024030623/0001213900-24-030623-index.htm"},{"fact_type":"material_agreement","fact_key":"704090345278aaa2390d350eb22730a3ed44195d","cik":1359931,"ticker":"TARA","company_name":"Protara Therapeutics, Inc.","filed_at":"2024-04-05T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Subscription Agreement","agreement_type":"equity_purchase","counterparty":"certain purchasers","effective_date":"2024-04-05","item_codes_triggered":["1.01"],"value_text":null},"claim":"Protara Therapeutics, Inc. entered into Subscription Agreement with certain purchasers (effective 2024-04-05).","evidence_excerpt":"On April 5, 2024, Protara Therapeutics, Inc. (the “Company”) entered into a Subscription Agreement (the “Subscription Agreement”) with certain purchasers (the “Purchasers”), pursuant to which the Company agreed to sell and issue to the Purchasers, in a private placement (the “Private Placement”), an aggregate of 9,143,380 shares (the “Shares”) of common stock of the Company, par value $0.001 per share (the “Common Stock”) and, for certain purchasers, pre-funded warrants (the “Pre-Funded Warrants”) to purchase an aggregate of 1,700,000 shares of Common Stock.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001213900-24-030623","anchor_url":"https://secwatch.observer/filing/0001213900-24-030623#claim-704090345278aaa2390d350eb22730a3ed44195d","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1359931/000121390024030623/0001213900-24-030623-index.htm"},{"fact_type":"executive_change","fact_key":"9148ac1aa6","cik":1359931,"ticker":"TARA","company_name":"Protara Therapeutics, Inc.","filed_at":"2024-03-18T23:59:59+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"routine","effective_date":"2024-04-11","interim":false,"role":"Chief Medical Officer","role_category":"other_named_officer","successor_name":null,"successor_named":false},"claim":"Jathin Bandari resigned as Chief Medical Officer at Protara Therapeutics, Inc..","evidence_excerpt":"On March 18, 2024, Protara Therapeutics, Inc. (the “Company”) announced that Jathin Bandari, M.D., Chief Medical Officer of the Company, will be resigning from the Company to explore other opportunities, including devoting more time to academic work, effective as of April 11, 2024.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001213900-24-023589","anchor_url":"https://secwatch.observer/filing/0001213900-24-023589#claim-9148ac1aa6","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1359931/000121390024023589/0001213900-24-023589-index.htm"},{"fact_type":"earnings_release","fact_key":"2b923bb5998542112d2c4e57df1f82e72f54c807","cik":1359931,"ticker":"TARA","company_name":"Protara Therapeutics, Inc.","filed_at":"2024-03-13T23:59:59+00:00","payload":{"eps_text":"$3.57 per share","guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"Net loss for the year ended December 31, 2023 was $40.4 million, or $3.57 per share","period_text":"the full year and fourth quarter ended December 31, 2023","report_date":"2024-03-13","result_type":"reported_results","revenue_text":null},"claim":"Protara Therapeutics, Inc. reported the full year and fourth quarter ended December 31, 2023 results: net income Net loss for the year ended December 31, 2023 was $40.4 million, or $3.57 per share, EPS $3.57 per share.","evidence_excerpt":"Protara Therapeutics, Inc. (the “Company”) announced its financial results for the quarter and year ended December 31, 2023","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001213900-24-021981","anchor_url":"https://secwatch.observer/filing/0001213900-24-021981#claim-2b923bb5998542112d2c4e57df1f82e72f54c807","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1359931/000121390024021981/0001213900-24-021981-index.htm"},{"fact_type":"earnings_release","fact_key":"da8a7013122bead854a89a0106f7af0a58d5d062","cik":1359931,"ticker":"TARA","company_name":"Protara Therapeutics, Inc.","filed_at":"2023-11-03T23:59:59+00:00","payload":{"eps_text":"$0.87 per share","guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"net loss of $9.9 million","period_text":"the third quarter ended September 30, 2023","report_date":"2023-11-03","result_type":"reported_results","revenue_text":null},"claim":"Protara Therapeutics, Inc. reported the third quarter ended September 30, 2023 results: net income net loss of $9.9 million, EPS $0.87 per share.","evidence_excerpt":"For the third quarter of 2023, Protara reported a net loss of $9.9 million, or $0.87 per share","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001213900-23-083011","anchor_url":"https://secwatch.observer/filing/0001213900-23-083011#claim-da8a7013122bead854a89a0106f7af0a58d5d062","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1359931/000121390023083011/0001213900-23-083011-index.htm"},{"fact_type":"earnings_release","fact_key":"2c6941d6ce2c7517a4bdc3ae20016a3deb418d28","cik":1359931,"ticker":"TARA","company_name":"Protara Therapeutics, Inc.","filed_at":"2023-08-03T23:59:59+00:00","payload":{"eps_text":"$1.00 per share","guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"net loss of $11.3 million, or $1.00 per share","period_text":"second quarter ended June 30, 2023","report_date":"2023-08-03","result_type":"reported_results","revenue_text":null},"claim":"Protara Therapeutics, Inc. reported second quarter ended June 30, 2023 results: net income net loss of $11.3 million, or $1.00 per share, EPS $1.00 per share.","evidence_excerpt":"For the second quarter of 2023, Protara reported a net loss of $11.3 million, or $1.00 per share, compared with a net loss of $8.5 million, or $0.76 per share, for the same period in 2022.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001213900-23-062780","anchor_url":"https://secwatch.observer/filing/0001213900-23-062780#claim-2c6941d6ce2c7517a4bdc3ae20016a3deb418d28","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1359931/000121390023062780/0001213900-23-062780-index.htm"},{"fact_type":"shareholder_vote","fact_key":"2dc379e61a6a6283e1d7c44769f788cf83cf89d8","cik":1359931,"ticker":"TARA","company_name":"Protara Therapeutics, Inc.","filed_at":"2023-06-08T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2023-06-07","outcome":"passed","proposal_text":"Advisory approval of the compensation of named executive officers","proposal_type":"say_on_pay","results":[{"broker_non_votes":"2,255,211","subject":null,"votes_abstain":"62,576","votes_against":"296,338","votes_for":"5,571,777","votes_withheld":null}]},"claim":"Protara Therapeutics, Inc. shareholders approved Advisory approval of the compensation of named executive officers at the 2023-06-07 meeting.","evidence_excerpt":"Proposal 3. Approval, on an Advisory Basis, of the Compensation of the Company’s Named Executive Officers. The Company’s stockholders approved, on an advisory basis, the compensation of the Company’s named executive officers, as disclosed in the Company’s definitive proxy statement for the Annual Meeting. The final voting results were as follows: Votes For Votes Against Abstentions Broker Non-Votes 5,571,777 296,338 62,576 2,255,211","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001213900-23-047460","anchor_url":"https://secwatch.observer/filing/0001213900-23-047460#claim-2dc379e61a6a6283e1d7c44769f788cf83cf89d8","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1359931/000121390023047460/0001213900-23-047460-index.htm"},{"fact_type":"shareholder_vote","fact_key":"044838884127258ffef5662f130127a0f57b972e","cik":1359931,"ticker":"TARA","company_name":"Protara Therapeutics, Inc.","filed_at":"2023-06-08T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2023-06-07","outcome":"passed","proposal_text":"Ratification of the selection of Ernst and Young LLP as independent registered public accounting firm","proposal_type":"auditor_ratification","results":[{"broker_non_votes":null,"subject":null,"votes_abstain":"709","votes_against":"29,326","votes_for":"8,155,867","votes_withheld":null}]},"claim":"Protara Therapeutics, Inc. shareholders approved Ratification of the selection of Ernst and Young LLP as independent registered public accounting firm at the 2023-06-07 meeting.","evidence_excerpt":"Proposal 2. Ratification of the Selection of Independent Registered Public Accounting Firm. The Company’s stockholders ratified the selection by the Company’s Audit Committee of the Board of Ernst and Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023. The final voting results were as follows: Votes For Votes Against Abstentions 8,155,867 29,326 709","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001213900-23-047460","anchor_url":"https://secwatch.observer/filing/0001213900-23-047460#claim-044838884127258ffef5662f130127a0f57b972e","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1359931/000121390023047460/0001213900-23-047460-index.htm"},{"fact_type":"shareholder_vote","fact_key":"5b70fe5692a710b10aabe1398fd1336262dacef8","cik":1359931,"ticker":"TARA","company_name":"Protara Therapeutics, Inc.","filed_at":"2023-06-08T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2023-06-07","outcome":"passed","proposal_text":"Election of three Class III directors","proposal_type":"director_election","results":[{"broker_non_votes":"2,255,211","subject":"Jesse Shefferman","votes_abstain":null,"votes_against":null,"votes_for":"5,677,709","votes_withheld":"252,982"},{"broker_non_votes":"2,255,211","subject":"Barry Flannelly, Pharm. D.","votes_abstain":null,"votes_against":null,"votes_for":"5,625,929","votes_withheld":"304,762"},{"broker_non_votes":"2,255,211","subject":"Cynthia Smith","votes_abstain":null,"votes_against":null,"votes_for":"5,663,928","votes_withheld":"266,763"}]},"claim":"Protara Therapeutics, Inc. shareholders approved Election of three Class III directors at the 2023-06-07 meeting.","evidence_excerpt":"Proposal 1. Election of Directors. The Company’s stockholders elected the three persons listed below as Class III directors, each to serve on the Company’s Board of Directors until the Company’s 2026 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified. The final voting results were as follows: Votes For Votes Withheld Broker Non-Votes Jesse Shefferman 5,677,709 252,982 2,255,211 Barry Flannelly, Pharm. D. 5,625,929 304,762 2,255,211 Cynthia Smith 5,663,928 266,763 2,255,211","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001213900-23-047460","anchor_url":"https://secwatch.observer/filing/0001213900-23-047460#claim-5b70fe5692a710b10aabe1398fd1336262dacef8","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1359931/000121390023047460/0001213900-23-047460-index.htm"},{"fact_type":"earnings_release","fact_key":"2c75ca4cb5c1deeef23dcdd9dc9ee09f1d000c17","cik":1359931,"ticker":"TARA","company_name":"Protara Therapeutics, Inc.","filed_at":"2023-05-04T23:59:59+00:00","payload":{"eps_text":"$0.80 per share","guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"a net loss of $9.0 million","period_text":"first quarter ended March 31, 2023","report_date":"2023-05-04","result_type":"reported_results","revenue_text":null},"claim":"Protara Therapeutics, Inc. reported first quarter ended March 31, 2023 results: net income a net loss of $9.0 million, EPS $0.80 per share.","evidence_excerpt":"For the first quarter of 2023, Protara reported a net loss of $9.0 million, or $0.80 per share, compared with a net loss of $10.8 million, or $0.96 per share, for the same period in 2022.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001213900-23-036112","anchor_url":"https://secwatch.observer/filing/0001213900-23-036112#claim-2c75ca4cb5c1deeef23dcdd9dc9ee09f1d000c17","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1359931/000121390023036112/0001213900-23-036112-index.htm"},{"fact_type":"earnings_release","fact_key":"9f0df817c2188c3167a70f31917b8d5ffcfae19c","cik":1359931,"ticker":"TARA","company_name":"Protara Therapeutics, Inc.","filed_at":"2023-03-08T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"net loss of $39.0 million, or $3.46 per share","period_text":"the quarter and year ended December 31, 2022","report_date":"2023-03-08","result_type":"reported_results","revenue_text":null},"claim":"Protara Therapeutics, Inc. reported the quarter and year ended December 31, 2022 results: net income net loss of $39.0 million, or $3.46 per share.","evidence_excerpt":"On March 8, 2023, Protara Therapeutics, Inc. (the “Company”) announced its financial results for the quarter and year ended December 31, 2022 in the press release attached hereto as Exhibit 99.1 and incorporated herein by reference.","confidence":0.5,"filing_url":"https://secwatch.observer/filing/0001213900-23-018371","anchor_url":"https://secwatch.observer/filing/0001213900-23-018371#claim-9f0df817c2188c3167a70f31917b8d5ffcfae19c","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1359931/000121390023018371/0001213900-23-018371-index.htm"},{"fact_type":"executive_change","fact_key":"b603b6da12","cik":1359931,"ticker":"TARA","company_name":"Protara Therapeutics, Inc.","filed_at":"2023-01-30T23:59:59+00:00","payload":{"action":"replaced","action_category":"role_change","departure_tone":"routine","effective_date":"2023-01-30","interim":false,"role":"Chief Financial Officer","role_category":"cfo","successor_name":"Patrick Fabbio","successor_named":true},"claim":"Jesse Shefferman changed role as Chief Financial Officer at Protara Therapeutics, Inc..","evidence_excerpt":"Mr. Fabbio will serve as the Company’s principal financial officer effective January 30, 2023, replacing Jesse Shefferman, the Company’s President and Chief Executive Officer, who had been serving in such role while the Company searched for a Chief Financial Officer.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001213900-23-005811","anchor_url":"https://secwatch.observer/filing/0001213900-23-005811#claim-b603b6da12","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1359931/000121390023005811/0001213900-23-005811-index.htm"},{"fact_type":"executive_change","fact_key":"697717c858","cik":1359931,"ticker":"TARA","company_name":"Protara Therapeutics, Inc.","filed_at":"2023-01-30T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2023-01-30","interim":false,"role":"Chief Financial Officer","role_category":"cfo","successor_name":null,"successor_named":false},"claim":"Patrick Fabbio was appointed as Chief Financial Officer at Protara Therapeutics, Inc..","evidence_excerpt":"On January 30, 2023, Protara Therapeutics, Inc. (the “Company”) announced that, effective as of January 30, 2023, Patrick Fabbio had been appointed as Chief Financial Officer of the Company.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001213900-23-005811","anchor_url":"https://secwatch.observer/filing/0001213900-23-005811#claim-697717c858","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1359931/000121390023005811/0001213900-23-005811-index.htm"},{"fact_type":"earnings_release","fact_key":"de2748d353511e490ee9d9bf573ec2ed1fc7ec8d","cik":1359931,"ticker":"TARA","company_name":"Protara Therapeutics, Inc.","filed_at":"2022-11-03T23:59:59+00:00","payload":{"eps_text":"$0.68 per share","guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"net loss of $7.7 million, or $0.68 per share","period_text":"the third quarter ended September 30, 2022","report_date":"2022-11-03","result_type":"reported_results","revenue_text":null},"claim":"Protara Therapeutics, Inc. reported the third quarter ended September 30, 2022 results: net income net loss of $7.7 million, or $0.68 per share, EPS $0.68 per share.","evidence_excerpt":"Protara Therapeutics, Inc. (the “Company”) announced its financial results for the quarter ended September 30, 2022 in the press release attached hereto as Exhibit 99.1 and incorporated herein by reference.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001213900-22-068819","anchor_url":"https://secwatch.observer/filing/0001213900-22-068819#claim-de2748d353511e490ee9d9bf573ec2ed1fc7ec8d","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1359931/000121390022068819/0001213900-22-068819-index.htm"},{"fact_type":"executive_change","fact_key":"b51a2c3bc9","cik":1359931,"ticker":"TARA","company_name":"Protara Therapeutics, Inc.","filed_at":"2022-07-18T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2022-07-16","interim":false,"role":"principal financial officer","role_category":"other_named_officer","successor_name":null,"successor_named":false},"claim":"Jesse Shefferman was appointed as principal financial officer at Protara Therapeutics, Inc..","evidence_excerpt":"Also effective July 16, 2022, Mr. Shefferman has been appointed as principal financial officer of the Company.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001213900-22-039976","anchor_url":"https://secwatch.observer/filing/0001213900-22-039976#claim-b51a2c3bc9","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1359931/000121390022039976/0001213900-22-039976-index.htm"},{"fact_type":"executive_change","fact_key":"1f5f653e9f","cik":1359931,"ticker":"TARA","company_name":"Protara Therapeutics, Inc.","filed_at":"2022-07-18T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2022-07-16","interim":false,"role":"Controller","role_category":"other_named_officer","successor_name":null,"successor_named":false},"claim":"Hannah Fry was appointed as Controller at Protara Therapeutics, Inc..","evidence_excerpt":"Effective July 16, 2022 (the “Effective Date”), Hannah Fry has been appointed to the role of Controller of the Company.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001213900-22-039976","anchor_url":"https://secwatch.observer/filing/0001213900-22-039976#claim-1f5f653e9f","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1359931/000121390022039976/0001213900-22-039976-index.htm"},{"fact_type":"executive_change","fact_key":"1af188fb83","cik":1359931,"ticker":"TARA","company_name":"Protara Therapeutics, Inc.","filed_at":"2022-07-18T23:59:59+00:00","payload":{"action":"left","action_category":"departure","departure_tone":"routine","effective_date":"2022-07-15","interim":false,"role":"Chief Financial Officer","role_category":"cfo","successor_name":"Jesse Shefferman","successor_named":true},"claim":"Blaine Davis departed as Chief Financial Officer at Protara Therapeutics, Inc..","evidence_excerpt":"Protara Therapeutics, Inc. (the “Company”) announced that Blaine Davis, the Chief Financial Officer of the Company, left the Company to pursue other opportunities on July 15, 2022.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001213900-22-039976","anchor_url":"https://secwatch.observer/filing/0001213900-22-039976#claim-1af188fb83","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1359931/000121390022039976/0001213900-22-039976-index.htm"},{"fact_type":"executive_change","fact_key":"60d18b1dc4","cik":1359931,"ticker":"TARA","company_name":"Protara Therapeutics, Inc.","filed_at":"2022-06-21T23:59:59+00:00","payload":{"action":"leaving","action_category":"departure","departure_tone":"routine","effective_date":"2022-07-15","interim":false,"role":"Chief Financial Officer","role_category":"cfo","successor_name":null,"successor_named":false},"claim":"Blaine Davis departed as Chief Financial Officer at Protara Therapeutics, Inc..","evidence_excerpt":"On June 21, 2022 Protara Therapeutics, Inc. (the “Company”) announced that Blaine Davis, Chief Financial Officer of the Company, will be leaving the Company to pursue other opportunities effective as of July 15, 2022.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001213900-22-033756","anchor_url":"https://secwatch.observer/filing/0001213900-22-033756#claim-60d18b1dc4","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1359931/000121390022033756/0001213900-22-033756-index.htm"},{"fact_type":"executive_change","fact_key":"f7935fa6ab","cik":1359931,"ticker":"TARA","company_name":"Protara Therapeutics, Inc.","filed_at":"2022-01-10T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2022-01-10","interim":false,"role":"Chief Medical Officer","role_category":"other_named_officer","successor_name":null,"successor_named":false},"claim":"Jathin Bandari was appointed as Chief Medical Officer at Protara Therapeutics, Inc..","evidence_excerpt":"Effective as of January 10, 2022 (the “Effective Date”), Protara Therapeutics, Inc. (the “Company”) appointed Jathin Bandari, M.D. as Chief Medical Officer of the Company.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001213900-22-001222","anchor_url":"https://secwatch.observer/filing/0001213900-22-001222#claim-f7935fa6ab","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1359931/000121390022001222/0001213900-22-001222-index.htm"},{"fact_type":"executive_change","fact_key":"a7294125d3","cik":1359931,"ticker":"TARA","company_name":"Protara Therapeutics, Inc.","filed_at":"2021-10-18T23:59:59+00:00","payload":{"action":"will no longer be employed","action_category":"departure","departure_tone":"routine","effective_date":"2021-10-15","interim":false,"role":"Chief Medical Officer","role_category":"other_named_officer","successor_name":null,"successor_named":false},"claim":"Martín Sebastian Olivo departed as Chief Medical Officer at Protara Therapeutics, Inc..","evidence_excerpt":"Effective October 15, 2021, Martín Sebastian Olivo, M.D. will no longer be employed by the Company as Chief Medical Officer","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001213900-21-053303","anchor_url":"https://secwatch.observer/filing/0001213900-21-053303#claim-a7294125d3","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1359931/000121390021053303/0001213900-21-053303-index.htm"}]}